The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Phase III randomized study of CPX-351 liposome for injection in older patients with newly diagnosed secondary acute myeloid leukemia
CPX-351 is a liposomal formulation of daunorubicin plus cytarabine co-encapsulated at a molar ratio of 1:5. Findings from a phase II randomized study demonstrated that CPX-351 led to higher remission rates and better survival in patients aged 60–75 years with newly diagnosed secondary acute myeloid leukemia (sAML) compared to standard 7+3 chemotherapy. As a result, a phase III open-label randomized study (NCT01696084), comparing the safety and efficacy of CPX-351 versus conventional 7+3 chemotherapy was conducted. The results from this pivotal phase III study were reported by Jeffery Lancet et al. in the Journal of Clinical Oncology.
Three-hundred and nine patients with newly diagnosed sAML were randomly assigned 1:1 to receive CPX-351 (n = 153, mean age = 67.8 years) or 7+3 (n = 156, mean age = 67.7) as induction and consolidation chemotherapy. The primary endpoint of the study was overall survival (OS).
Key findings:
- Median follow-up: 20.7 months
- Median OS in the CPX-351 and 7+3 cohort: 9.56 vs 5.95 months, HR = 0.69 (95% CI, 0.52–0.90), P = 0.003
- Median event-free survival (EFS) in the CPX-351 and 7+3 cohort: 2.53 vs 1.31 months, HR = 0.74 (95% CI, 0.58–0.96), P = 0.021
- Overall remission rate in the CPX-351 and 7+3 cohort: 47.7% vs 33.3%, P = 0.016
- Fifty-two patients of the 153 in the CPX-351 cohort and 39 patients of the 156 in the 7+3 cohort proceeded to transplant
- Most frequent grade 3–5 adverse events reported were febrile neutropenia (68.0% vs 70.9%), pneumonia (19.6% vs 14.6%) and hypoxia (13.1% vs 15.2%)
- Day-30 mortality rate in the CPX-351 and 7+3 cohort were 5.9% and 10.6% respectively, P = 0.149
- Day-60 mortality rate in the CPX-351 and 7+3 cohort were 13.7% and 21.2% respectively, P = 0.097
Findings from this pivotal phase III randomized study demonstrated that CPX-351 significantly improved OS, EFS, and remission rates compared to conventional 7+3 in older patients with newly diagnosed high-risk sAML. Based on the findings of this study, CPX-351 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with newly diagnosed therapy-related AML (t-AML) or newly diagnosed AML with myelodysplasia-related changes (AML-MRC) in August 2017. The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recently gave a positive opinion recommending marketing authorization for CPX-351 for the treatment of t-AML and AML-MRC.
References